UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments

Advanced materials (Weinheim), 2019-03, Vol.31 (10), p.e1806899-n/a

2019

Volltextzugriff (PDF)

CD133, Selectively Targeting the Root of Cancer

Toxins, 2016-05, Vol.8 (6), p.165

2016

Volltextzugriff (PDF)

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Blood, 2014-05, Vol.123 (19), p.3016-3026

2014

Volltextzugriff (PDF)

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies

Toxins, 2018-01, Vol.10 (1), p.32

2018

Volltextzugriff (PDF)

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

Clinical cancer research, 2015-03, Vol.21 (6), p.1267-1272

2015

Volltextzugriff (PDF)

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS

Blood advances, 2018-06, Vol.2 (12), p.1459-1469

2018

Volltextzugriff (PDF)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

Frontiers in immunology, 2023-02, Vol.14, p.1060905-1060905

2023

Volltextzugriff (PDF)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

Biomolecules (Basel, Switzerland), 2020-06, Vol.10 (6), p.956

2020

Volltextzugriff (PDF)

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development

Toxins, 2015-10, Vol.7 (10), p.4067-4082

2015

Volltextzugriff (PDF)

Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic

Journal of the American Chemical Society, 2010-12, Vol.132 (48), p.17247-17257

2010

Volltextzugriff (PDF)

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

International journal of cancer, 2013-10, Vol.133 (8), p.1936-1944

2013

Volltextzugriff (PDF)

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Clinical cancer research, 2016-07, Vol.22 (14), p.3440-3450

2016

Volltextzugriff (PDF)

Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings

Molecular cancer therapeutics, 2023-03, Vol.22 (3), p.371-380

2023

Volltextzugriff (PDF)

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells

Methods in molecular biology (Clifton, N.J.), 2016-01, Vol.1441, p.333

2016

Volltextzugriff (PDF)

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

Targeted oncology, 2014-09, Vol.9 (3), p.239-249

2014

Volltextzugriff (PDF)

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

Clinical cancer research, 2009-10, Vol.15 (19), p.6137-6147

2009

Volltextzugriff (PDF)

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker

Molecular therapy, 2016-08, Vol.24 (7), p.1312-1322

2016

Volltextzugriff (PDF)

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

Clinical cancer research, 2013-07, Vol.19 (14), p.3844-3855

2013

Volltextzugriff (PDF)

Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia

Molecular therapy, 2021-12, Vol.29 (12), p.3410-3421

2021

Volltextzugriff (PDF)

Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv

Clinical cancer research, 2007-05, Vol.13 (10), p.3058-3067

2007

Volltextzugriff (PDF)

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production

Molecular cancer therapeutics, 2012-12, Vol.11 (12), p.2674-2684

2012

Volltextzugriff (PDF)

A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer

Clinical cancer research, 2007-11, Vol.13 (21), p.6486-6493

2007

Volltextzugriff (PDF)

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker

Oncotarget, 2016-11, Vol.7 (45), p.73830-73844

2016

Volltextzugriff (PDF)

Prosthetic Antigen Receptors

Journal of the American Chemical Society, 2015-08, Vol.137 (32), p.10108-10111

2015

Volltextzugriff (PDF)

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

Blood advances, 2019-03, Vol.3 (6), p.897-907

2019

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(96)

Sprache

Englisch
(96)

Erscheinungsjahr

n.n

Thema

Science & Technology
(79)
Life Sciences & Biomedicine
(75)
Animals
(61)
Mice
(50)
Oncology
(41)
Biological And Medical Sciences
(36)
Medical Sciences
(35)
Cell Line, Tumor
(28)
Female
(23)
Mice, Nude
(23)
Immunotoxin
(20)
Bone Marrow Transplantation
(19)
Hematology
(19)
Male
(16)
Immunotoxins - Therapeutic Use
(15)
Disease Models, Animal
(14)
Pharmacology. Drug Treatments
(14)
Recombinant Fusion Proteins - Pharmacology
(14)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(13)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments

CD133, Selectively Targeting the Root of Cancer

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development

Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia

Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production

A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker

Prosthetic Antigen Receptors

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

Aktive Filter

Suchergebnisse filtern